Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Significance: Anti–CTLA-4 mAb is able to augment tumor immunity despite CTLA-4 expression by functionally opposing T cell populations: activated effector T (Teff) cells and FOXP3 + CD4 + Treg cells. Here we show that anti–CTLA-4 mAb engineered to be cytotoxic depleted Treg cells effectively in vitro in humans and in vivo in mice. It expanded antigen-specific CD8 + Teff cells when tumor-antigen stimulation was delayed several days to protect them from killing by the mAb. Anti–CTLA-4 mAb modified to exhibit a lesser or no cell-depleting activity failed to show such effects. This strategy of differentially controlling Treg and Teff cells by cytotoxic anti–CTLA-4 mAb to evoke effective tumor immunity will help in designing cancer immunotherapy targeting other molecules commonly expressed by Treg and Teff cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“New studies suggest that CTLA4 blockade within the TME could decrease the activation threshold of T cells while selectively depleting immunosuppressive regulatory T cells, which can increase the number of tumor‐specific CD8+ T cells [294].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [294]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 2×
“In agreement with these results, simultaneous treatment of ipilimumab and gp100 peptide vaccine in patients with metastatic melanoma showed slight reductions in overall survival compared with ipilimumab alone, suggesting that melanoma-antigen specific CD8 T cells with elevated CTLA-4 expression might have been concurr…”
BackgroundResultCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Anti-human CTLA-4 mAb, which has been shown to be clinically effective in treating melanoma (17, 18), was initially considered to block CTLA-4–mediated negative signal into activated effector T cells, sustaining their activated state in attacking tumor cells.”
BackgroundSakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306 · cited 1×
“N occurring CD25 CD4 Treg cells, which express the transcription factor FOXP3, play indispensable roles in the maintenance of immunological self-tolerance and homeostasis (1).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 1×
“One of various suppression mechanisms used by Treg cells is CTLA-4–dependent down-regulation of CD80 and CD86 expression by dendritic cells (DCs) (14, 15).”
BackgroundSelf-citationFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291 · cited 2×
“II eTreg cells, which highly express CTLA-4 (10).”
BackgroundSelf-citationRegulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Self-citationMechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754 · cited 1×
“One of various suppression mechanisms used by Treg cells is CTLA-4–dependent down-regulation of CD80 and CD86 expression by dendritic cells (DCs) (14, 15).”
BackgroundShimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Self-citationSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Shang, B., Liu, Y., Jiang, S.-J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep15179 · Cited by 985 · cited 1×
“In humans, there is accumulating evidence for abundant infiltration of Treg cells into various tumor tissues (6–8), and a significant correlation between Treg infiltration and poor prognosis in various types of cancers (9).”
BackgroundIncrease of regulatory T cells in the peripheral blood of cancer patients.
Wolf, A. M., Wolf, D. G. F., Steurer, M., Gastl, G. A., Gunsilius, E., & Grubeck-Loebenstein, B. (2003) · PubMed · Cited by 891
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 3×
“In contrast, with the presence of these three FOXP3 populations in the blood, the majority of tumors show predominant infiltration of eTreg cells, which appear to be suppressing effective antitumor immune responses in cancer patients (12).”
BackgroundMethodSelf-citationSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627 · cited 1×
“is instrumental in evoking and augmenting antitumor immune responses, as demonstrated recently with some monoclonal antibodies (mAbs) specific for the molecules specifically expressed by eTreg cells (13).”
BackgroundSelf-citationIntracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR Engagement
Linsley, P. S., Bradshaw, J., Greene, J., Peach, R., Bennett, K. L., & Mittler, R. S. (1996) · Immunity · doi:10.1016/s1074-7613(00)80480-x · Cited by 609
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601 · cited 1×
“It was also reported that ipilimumab treatment of melanoma patients significantly reduced FOXP3 Treg cells in the tumor tissues particularly in clinical responders (29).”
BackgroundFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Self-citationEgen, J. G., & Allison, J. P. (2002) · Immunity · doi:10.1016/s1074-7613(01)00259-x · Cited by 535
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477 · cited 1×
“In agreement with these results, simultaneous treatment of ipilimumab and gp100 peptide vaccine in patients with metastatic melanoma showed slight reductions in overall survival compared with ipilimumab alone, suggesting that melanoma-antigen specific CD8 T cells with elevated CTLA-4 expression might have been concurr…”
ResultKo, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050940 · Cited by 466
Self-citationKo, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.200509402092c · Cited by 462 · cited 1×
“inoculation while no tumor regression by the mAb treatment on the same day or after the tumor inoculation (33).”
BackgroundSelf-citationBulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446 · cited 1×
“Similarly, antibodies against GITR, OX40, and CD25 molecules, which tumor-infiltrating Treg cells express the highest amounts, were shown to be dependent on ADCC-mediated depletion of Treg cells in tumor rejection (19, 26, 28).”
BackgroundPetersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M., Harpole, D. H., & Patz, E. F. (2006) · Cancer · doi:10.1002/cncr.22282 · Cited by 433
Arce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418 · cited 1×
“Similarly, antibodies against GITR, OX40, and CD25 molecules, which tumor-infiltrating Treg cells express the highest amounts, were shown to be dependent on ADCC-mediated depletion of Treg cells in tumor rejection (19, 26, 28).”
BackgroundNY‐ESO‐1: Review of an Immunogenic Tumor Antigen
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95001-5 · Cited by 405 · cited 1×
“Next, we assessed the effects of these Fc-engineered mAbs on in vitro antigen-specific expansion of CD8 T cells by stimulating PBMCs from HLA-A*0201–expressing healthy donors or melanoma patients for 9 d with various peptides, for example: derived from Melan-A/MART-1, a self/tumor-antigen expressed by normal melanocyt…”
BackgroundSelf-citationOX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2014.26 · Cited by 284 · cited 1×
“Similarly, antibodies against GITR, OX40, and CD25 molecules, which tumor-infiltrating Treg cells express the highest amounts, were shown to be dependent on ADCC-mediated depletion of Treg cells in tumor rejection (19, 26, 28).”
BackgroundA distinct subpopulation of CD25 − T-follicular regulatory cells localizes in the germinal centers
Wing, J. B., Kitagawa, Y., Locci, M., Hume, H., Tay, C., Morita, T., Kidani, Y., Matsuda, K., Inoue, T., Kurosaki, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705551114 · Cited by 211 · cited 11×
“The reconstructed mAb showed 1,000-fold higher binding affinity for human FcγRIIIa than unmodified mAb without increasing the affinity for inhibitory FcγRIIb.”
Self-citationDetection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
Maeda, Y., Nishikawa, H., Sugiyama, D., Ha, D., Hamaguchi, M., Saito, T., Nishioka, M., Wing, J. B., Adeegbe, D., Katayama, I., et al. (2014) · Science · doi:10.1126/science.aaa1292 · Cited by 200 · cited 2×
“These staining procedures were performed before fixation and permeabilization, as described in our previous study (24).”
BackgroundMethodSelf-citationBarcoding of Live Human Peripheral Blood Mononuclear Cells for Multiplexed Mass Cytometry
Mei, H. E., Leipold, M. D., Schulz, A. R., Chester, C., & Maecker, H. T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402661 · Cited by 166 · cited 1×
“For human PBMCs and TILs, cell suspensions were barcoded by anti-CD45 antibodies with various metal-conjugates, as described previously (35), before staining with 198-cisplatin for dead cell discrimination and then antibody staining with the following panel.”
MethodMimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., Shida-Kawazoe, M., & Hattori, K. (2013) · mAbs · doi:10.4161/mabs.23452 · Cited by 74
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
Self-citationPD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
“These data suggest that antibodies, especially cell-depleting ones, targeting CTLA-4, OX-40, and CCR4 can be used for the treatment and prevention of HPD by specifically depleting eTreg cells (28).”
BackgroundSelf-citationLi, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
“However, the ADCC strategy is unlikely to succeed in colorectal, liver, prostate and ovarian cancer treatments [170, 171].”
BackgroundChauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 794
“59 Because Tregs highly express TIGIT in the TME, one wonders whether anti-TIGIT mAbs with Fc-binding capability induce Treg depletion.”
Background
Metadata
- Authors
- Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., Katayama, I., Nishikawa, H., & Sakaguchi, S.
- Affiliations
- Kyoto University (JP)
- Immunology Frontier Research Center, The University of Osaka (JP)
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- The University of Osaka (JP)
- Agency for Science, Technology and Research (SG)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-12-26
- Volume
- 116
- Issue
- 2
- Pages
- 609-618
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6329979
- OpenAlex
- W2907885272
- Cited by
- 205
- References
- 37
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 31 · 2023: 22 · 2022: 41 · 2021: 24 · 2020: 33 · 2019: 17
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OUKA (Osaka University Knowledge Archive) (Osaka University) (submittedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (16H006295)
- Japan Agency for Medical Research and Development (JP18cm0106303)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- anti-CTLA-4 antibody, CTLA-4, regulatory T cells, Foxp3, effector T cells, CD8+ T cells, antitumor immunity, cancer immunotherapy, Fc-engineered antibody, antibody cytotoxicity, Treg depletion
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Antibody-Dependent Cell Cytotoxicity, Humans, Mice, Inbred BALB C, Neoplasms, CD8-Positive T-Lymphocytes, Cancer Vaccines, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.